I just cruised through the 10-K again, and I noted that all enthusiasm about Lilly independently developing compounds is missing. Lots of reason to be encouraged, but for VGCC, here's the summary......
Currently, SIBIA is focusing on small molecule VGCC antagonists for
the treatment of pain. This derives from the observation that a synthetic
version of a VGCC subtype-selective peptide, (OMEGA)-conotoxin MVIIA, is
currently in late stage clinical development by a third party for chronic pain.
This molecule has demonstrated efficacy, but its widespread use may be limited
by its peptidic nature and by the fact that it must be administered into the
spinal fluid by a pump. The Company believes that this validates a particular
VGCC subtype as a molecular target for pain, and that small molecule drugs of
the type SIBIA is identifying will offer significant advantages over peptides or
their derivatives in creating a useful drug for chronic pain, where great unmet
need exists. In addition, recent studies have identified specific mutations in
one of the Company's proprietary human VGCC genes associated with an inherited
form of migraine. The Company believes this provides insight as to a novel
therapeutic approach for the treatment of migraine.
I really thought that this program would be licensed by now. As usual, the further the program goes without partnering, the more valuable, BUT..... we've been looking at "SIBIA is currently free to develop compounds and other technology
it discovers in this area on its own or with partners" for two years now. |
